The Medical Letter®

on Drugs and Therapeutics

Volume 64 **Published Online August 8, 2022**

Online Article

IN THIS ISSUE

The Medical Letter®
on Drugs and Therapeutics

Volume 64 Published online August 8, 2022

Online Article

IN THIS ISSUE

COVID-19 UPDATE

Dosing Interval for Tixagevimab/Cilgavimab *(Evusheld)*

The FDA has amended its Emergency Use Authorization (EUA) for the investigational long-acting monoclonal antibodies tixagevimab and cilgavimab (*Evusheld* – AstraZeneca) to recommend repeat dosing every 6 months in patients who require ongoing protection against COVID-19.[1] *Evusheld* is authorized for IM pre-exposure prophylaxis of COVID-19 in persons ≥12 years old who weigh ≥40 kg and have either a history of a severe adverse reaction that prevents their vaccination against COVID-19 or moderate or severe immune compromise.[2]

The revision was based on pharmacologic modeling data, which suggest that tixagevimab and cilgavimab retain activity against currently circulating variants of SARS-CoV-2 (including the Omicron variants BA.2, BA.2.12.1, BA.4, and BA.5) for 6 months after administration of a 300-mg dose of each antibody.[2]

The recommended dosage of *Evusheld* is 300 mg of tixagevimab and 300 mg of cilgavimab given as two consecutive IM injections once every 6 months. Patients should be monitored for at least 1 hour after administration. *Evusheld* should not be used for treatment or post-exposure prophylaxis of COVID-19, or within 2 weeks after administration of a COVID-19 vaccine.[2] ■

1. FDA. FDA authorizes revisions to Evusheld dosing. June 29, 2022. Available at: https://bit.ly/3K5AcNc. Accessed July 11, 2022.
2. FDA. Fact sheet for health care providers: Emergency Use Authorization for Evusheld (tixagevimab co-packaged with cilgavimab). June 2022. Available at: https://bit.ly/3IWpQjg. Accessed July 11, 2022.

The Medical Letter® Vol. 64 Published online August 8, 2022

Subscription Services

Address:
The Medical Letter, Inc.
145 Huguenot St. Ste. 312
New Rochelle, NY 10801-7537
www.medicalletter.org

Customer Service:
Call: 800-211-2769 or 914-235-0500
Fax: 914-632-1733
E-mail: custserv@medicalletter.org

Permissions:
To reproduce any portion of this issue, please e-mail your request to: permissions@medicalletter.org

Subscriptions (US):
1 year - $159; 2 years - $298;
3 years - $398. $65 per year for students, interns, residents, and fellows in the US and Canada.
Reprints - $45 per issue or article

Site License Inquiries:
E-mail: SubQuote@medicalletter.org
Call: 800-211-2769
Special rates available for bulk subscriptions.

Get Connected: